At the same time, there was an increase in immunoreactivity for the phosphorylated form of FGFR1 in patients with moderate and severe coronary artery disease (CAD), implying an increase in FGF signaling (Fig 4E and F). Here, FGFR1 is linked to coronary artery disorder.